On October 19, 2025, Verastem, Inc. reported positive safety and efficacy results for its drug VS-7375 in a study involving 66 pancreatic cancer patients, showing a 40.7% response rate and 96.7% disease control rate. Most patients experienced tumor reduction, with a median progression-free survival of 5.52 months; safety profiles were consistent with previous data.